Sino Biopharm (01177) opened sharply higher, climbing over 5% in early Hong Kong trading. At press time, shares advanced 5.49% to HK$6.72 with turnover reaching HK$52.35 million.
The pharmaceutical giant announced acquiring 95.09% of Shanghai Lixin Pharmaceuticals for approximately $500 million. Combined with its existing 4.91% stake obtained during Lixin's Series C financing, the transaction will make Lixin a wholly-owned subsidiary.
Industry records reveal Lixin's significant licensing achievements: - In May 2023, AstraZeneca secured exclusive global rights to develop and commercialize LM-305, involving $55 million upfront payment and potential milestones up to $545 million. - In November 2024, Merck & Co. obtained worldwide exclusive rights to PD-1/VEGF bispecific antibody LM-299, generating $3.288 billion including $888 million in upfront and technology transfer milestone payments.
Cumulatively, Lixin has secured nearly $4 billion in out-licensing deals, equivalent to approximately ¥30 billion RMB. This acquisition positions Sino Biopharm to capitalize on Lixin's innovative pipeline and robust partnership portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.